Cover Image
市場調查報告書

前列腺癌:開發中產品分析

Prostate Cancer - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 232770
出版日期 內容資訊 英文 1845 Pages
訂單完成後即時交付
價格
Back to Top
前列腺癌:開發中產品分析 Prostate Cancer - Pipeline Review, H1 2017
出版日期: 2017年06月30日 內容資訊: 英文 1845 Pages
簡介

前列腺癌是由於前列腺發病的癌症之一,男性,尤其是高齡的男性患病。主要的症狀有排尿時麻煩和力量低,血尿,腰、臀部、大腿部等的疼痛等。易罹病素質中包含年齡和家族病史,肥胖症等。主要的治療方法有外科手術和化療,放射治療等。

本報告提供全球各國的前列腺癌治療用的開發中產品的開發情形相關分析,產品開發、上市的最新趨勢,及臨床實驗的各階段的產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊,為您概述為以下內容。

簡介

前列腺癌概要

治療藥的開發

前列腺癌:企業開發中的治療藥

前列腺癌:大學/機關研究中的治療藥

前列腺癌:開發中產品概況

前列腺癌:企業開發中的產品

前列腺癌:大學/機關研究中的產品

前列腺癌的治療藥開發作的企業

前列腺癌:治療藥的評估

藥物簡介

前列腺癌:暫停中的計劃

前列腺癌:開發中止的產品

前列腺癌:產品開發的里程碑

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9476IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Prostate Cancer - Pipeline Review, H1 2017, provides an overview of the Prostate Cancer (Oncology) pipeline landscape.

Prostate cancer is a form of cancer that affects men and starts off in the prostate gland. Prostate cancer usually occurs in older men. Symptoms include trouble urinating, decreased force in the stream of urine, blood in the urine, pain in the lower back, hips or thighs, bone pain and erectile dysfunction. Predisposing factors include age, family history and obesity. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Prostate Cancer - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Prostate Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Prostate Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Prostate Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 18, 98, 108, 6, 247, 35 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 11, 15, 58 and 20 molecules, respectively.

Prostate Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Prostate Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Prostate Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Prostate Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Prostate Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Prostate Cancer (Oncology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Prostate Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Prostate Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Prostate Cancer - Overview
  • Prostate Cancer - Therapeutics Development
  • Prostate Cancer - Therapeutics Assessment
  • Prostate Cancer - Companies Involved in Therapeutics Development
  • Prostate Cancer - Drug Profiles
  • Prostate Cancer - Dormant Projects
  • Prostate Cancer - Discontinued Products
  • Prostate Cancer - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Prostate Cancer, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..6), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..7), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..8), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..9), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..10), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..11), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..12), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..13), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..14), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..15), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..16), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..17), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..18), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017 (Contd..3), H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..4), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..5), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..6), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..7), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..8), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..9), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..10), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..11), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..12), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..13), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..14), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..15), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..16), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..17), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..18), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..19), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..20), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..21), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..22), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..23), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..24), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..25), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..26), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..27), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..28), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
  • Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017
  • Products under Development by Universities/Institutes, H1 2017 (Contd..3), H1 2017
  • Products under Development by Universities/Institutes, H1 2017 (Contd..4), H1 2017
  • Products under Development by Universities/Institutes, H1 2017 (Contd..5), H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..4), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..5), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..6), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..7), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..8), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..9), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..10), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..11), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..12), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..13), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..5), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..6), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..7), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..8), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..9), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..10), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..11), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..12), H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017 (Contd..1), H1 2017
  • Prostate Cancer - Pipeline by 3-V Biosciences Inc, H1 2017
  • Prostate Cancer - Pipeline by 4SC AG, H1 2017
  • Prostate Cancer - Pipeline by AB Science SA, H1 2017
  • Prostate Cancer - Pipeline by AbbVie Inc, H1 2017
  • Prostate Cancer - Pipeline by Actinium Pharmaceuticals Inc, H1 2017
  • Prostate Cancer - Pipeline by ADC Therapeutics Sarl, H1 2017
  • Prostate Cancer - Pipeline by Addex Therapeutics Ltd, H1 2017
  • Prostate Cancer - Pipeline by Aduro BioTech Inc, H1 2017
  • Prostate Cancer - Pipeline by Advanced Accelerator Applications SA, H1 2017
  • Prostate Cancer - Pipeline by Advanced Cancer Therapeutics LLC, H1 2017
  • Prostate Cancer - Pipeline by Advantagene Inc, H1 2017
  • Prostate Cancer - Pipeline by Advaxis Inc, H1 2017
  • Prostate Cancer - Pipeline by Aeglea BioTherapeutics Inc, H1 2017
  • Prostate Cancer - Pipeline by Aeolus Pharmaceuticals Inc, H1 2017
  • Prostate Cancer - Pipeline by Aeterna Zentaris Inc, H1 2017
  • Prostate Cancer - Pipeline by Akshaya Bio Inc, H1 2017
  • Prostate Cancer - Pipeline by Alchemia Ltd, H1 2017
  • Prostate Cancer - Pipeline by Alethia Biotherapeutics Inc, H1 2017
  • Prostate Cancer - Pipeline by Alissa Pharma, H1 2017
  • Prostate Cancer - Pipeline by Almac Discovery Ltd, H1 2017
  • Prostate Cancer - Pipeline by Ambrx Inc, H1 2017
  • Prostate Cancer - Pipeline by Amgen Inc, H1 2017
  • Prostate Cancer - Pipeline by Anavex Life Sciences Corp, H1 2017
  • Prostate Cancer - Pipeline by AndroScience Corp, H1 2017
  • Prostate Cancer - Pipeline by AnGes MG Inc, H1 2017
  • Prostate Cancer - Pipeline by AntiCancer Inc, H1 2017
  • Prostate Cancer - Pipeline by Antigen Express Inc, H1 2017
  • Prostate Cancer - Pipeline by Antisense Therapeutics Ltd, H1 2017
  • Prostate Cancer - Pipeline by Apcure SAS, H1 2017
  • Prostate Cancer - Pipeline by Aphios Corp, H1 2017
  • Prostate Cancer - Pipeline by APIM Therapeutics AS, H1 2017
  • Prostate Cancer - Pipeline by Aptevo Therapeutics Inc, H1 2017
  • Prostate Cancer - Pipeline by Aptose Biosciences Inc, H1 2017
  • Prostate Cancer - Pipeline by ARMO Biosciences Inc, H1 2017
  • Prostate Cancer - Pipeline by Armour Therapeutics Inc, H1 2017
  • Prostate Cancer - Pipeline by Arno Therapeutics Inc, H1 2017
  • Prostate Cancer - Pipeline by ArQule Inc, H1 2017
  • Prostate Cancer - Pipeline by Arrien Pharmaceuticals LLC, H1 2017
  • Prostate Cancer - Pipeline by Arrowhead Pharmaceuticals Inc, H1 2017
  • Prostate Cancer - Pipeline by Arvinas Inc, H1 2017
  • Prostate Cancer - Pipeline by Asana BioSciences LLC, H1 2017
  • Prostate Cancer - Pipeline by Asieris Pharmaceuticals Co Ltd, H1 2017
  • Prostate Cancer - Pipeline by Astellas Pharma Inc, H1 2017
  • Prostate Cancer - Pipeline by AstraZeneca Plc, H1 2017
  • Prostate Cancer - Pipeline by Aurigene Discovery Technologies Ltd, H1 2017
  • Prostate Cancer - Pipeline by Avipep Pty Ltd, H1 2017
  • Prostate Cancer - Pipeline by Bavarian Nordic A/S, H1 2017
  • Prostate Cancer - Pipeline by Bayer AG, H1 2017
  • Prostate Cancer - Pipeline by BeiGene (Beijing) Co Ltd, H1 2017
  • Prostate Cancer - Pipeline by Bexion Pharmaceuticals LLC, H1 2017
  • Prostate Cancer - Pipeline by BHR Pharma LLC, H1 2017
  • Prostate Cancer - Pipeline by Bio-Cancer Treatment International Ltd, H1 2017
  • Prostate Cancer - Pipeline by Biotest AG, H1 2017
  • Prostate Cancer - Pipeline by Biscayne Pharmaceuticals Inc, H1 2017
  • Prostate Cancer - Pipeline by Blirt SA, H1 2017
  • Prostate Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2017
  • Prostate Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2017
  • Prostate Cancer - Pipeline by Bukwang Pharm Co Ltd, H1 2017
  • Prostate Cancer - Pipeline by Camurus AB, H1 2017
  • Prostate Cancer - Pipeline by Can-Fite BioPharma Ltd, H1 2017
  • Prostate Cancer - Pipeline by CanBas Co Ltd, H1 2017
  • Prostate Cancer - Pipeline by Cantex Pharmaceuticals Inc, H1 2017
  • Prostate Cancer - Pipeline by CEL-SCI Corp, H1 2017
  • Prostate Cancer - Pipeline by Celgene Corp, H1 2017
  • Prostate Cancer - Pipeline by CellCentric Ltd, H1 2017
  • Prostate Cancer - Pipeline by Celldex Therapeutics Inc, H1 2017
  • Prostate Cancer - Pipeline by Cellectar Biosciences Inc, H1 2017
  • Prostate Cancer - Pipeline by Cellmid Ltd, H1 2017
  • Prostate Cancer - Pipeline by Cellular Biomedicine Group Inc, H1 2017
  • Prostate Cancer - Pipeline by Celprogen Inc, H1 2017
  • Prostate Cancer - Pipeline by Chamaeleo Pharma NV, H1 2017
  • Prostate Cancer - Pipeline by Clovis Oncology Inc, H1 2017
  • Prostate Cancer - Pipeline by CohBar Inc, H1 2017
  • Prostate Cancer - Pipeline by Colby Pharmaceutical Company, H1 2017
  • Prostate Cancer - Pipeline by Corcept Therapeutics Inc, H1 2017
  • Prostate Cancer - Pipeline by Corvus Pharmaceuticals Inc, H1 2017
  • Prostate Cancer - Pipeline by Crescendo Biologics Ltd, H1 2017
  • Prostate Cancer - Pipeline by Curadis GmbH, H1 2017
  • Prostate Cancer - Pipeline by CytomX Therapeutics Inc, H1 2017
  • Prostate Cancer - Pipeline by Cytori Therapeutics Inc, H1 2017
  • Prostate Cancer - Pipeline by CytoVac A/S, H1 2017
  • Prostate Cancer - Pipeline by CZ BioMed Corp, H1 2017
  • Prostate Cancer - Pipeline by Daewoong Co Ltd, H1 2017
  • Prostate Cancer - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2017
  • Prostate Cancer - Pipeline by Deciphera Pharmaceuticals LLC, H1 2017
  • Prostate Cancer - Pipeline by DEKK-TEC Inc, H1 2017
  • Prostate Cancer - Pipeline by DexTech Medical AB, H1 2017
  • Prostate Cancer - Pipeline by Diffusion Pharmaceuticals Inc, H1 2017
  • Prostate Cancer - Pipeline by DNJ Pharma Inc, H1 2017
  • Prostate Cancer - Pipeline by Dongkook Pharmaceutical Co Ltd, H1 2017
  • Prostate Cancer - Pipeline by Eisai Co Ltd, H1 2017
  • Prostate Cancer - Pipeline by Eli Lilly and Company, H1 2017
  • Prostate Cancer - Pipeline by Enceladus Pharmaceuticals BV, H1 2017
  • Prostate Cancer - Pipeline by EndoCeutics Inc, H1 2017
  • Prostate Cancer - Pipeline by Endocyte Inc, H1 2017
  • Prostate Cancer - Pipeline by EntreChem SL, H1 2017
  • Prostate Cancer - Pipeline by EOS Biosciences Inc, H1 2017
  • Prostate Cancer - Pipeline by Errant Gene Therapeutics LLC, H1 2017
  • Prostate Cancer - Pipeline by Esperance Pharmaceuticals Inc, H1 2017
  • Prostate Cancer - Pipeline by ESSA Pharma Inc, H1 2017
  • Prostate Cancer - Pipeline by Eureka Therapeutics Inc, H1 2017
  • Prostate Cancer - Pipeline by Evgen Pharma Plc, H1 2017
  • Prostate Cancer - Pipeline by Exonate Ltd, H1 2017
  • Prostate Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
  • Prostate Cancer - Pipeline by Ferring International Center SA, H1 2017
  • Prostate Cancer - Pipeline by Foresee Pharmaceuticals LLC, H1 2017
  • Prostate Cancer - Pipeline by Fountain Biopharma Inc, H1 2017
  • Prostate Cancer - Pipeline by Fujifilm Corp, H1 2017
  • Prostate Cancer - Pipeline by G1 Therapeutics Inc, H1 2017
  • Prostate Cancer - Pipeline by Galectin Therapeutics Inc, H1 2017
  • Prostate Cancer - Pipeline by Genelux Corp, H1 2017
  • Prostate Cancer - Pipeline by Genentech Inc, H1 2017
  • Prostate Cancer - Pipeline by GeneSegues Inc, H1 2017
  • Prostate Cancer - Pipeline by Genmab A/S, H1 2017
  • Prostate Cancer - Pipeline by Gilead Sciences Inc, H1 2017
  • Prostate Cancer - Pipeline by Glactone Pharma AB, H1 2017
  • Prostate Cancer - Pipeline by GlaxoSmithKline Plc, H1 2017
  • Prostate Cancer - Pipeline by GlycoMimetics Inc, H1 2017
  • Prostate Cancer - Pipeline by GP Pharm SA, H1 2017
  • Prostate Cancer - Pipeline by GTx Inc, H1 2017
  • Prostate Cancer - Pipeline by Hadasit Medical Research Services & Development Ltd, H1 2017
  • Prostate Cancer - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017
  • Prostate Cancer - Pipeline by Health Ever Bio-Tech Co Ltd, H1 2017
  • Prostate Cancer - Pipeline by HitGen LTD, H1 2017
  • Prostate Cancer - Pipeline by Hybrigenics SA, H1 2017
  • Prostate Cancer - Pipeline by IC-MedTech Inc, H1 2017
  • Prostate Cancer - Pipeline by Ideaya Biosciences Inc, H1 2017
  • Prostate Cancer - Pipeline by IGF Oncology LLC, H1 2017
  • Prostate Cancer - Pipeline by Ignyta Inc, H1 2017
  • Prostate Cancer - Pipeline by Ildong Pharmaceutical Co Ltd, H1 2017
  • Prostate Cancer - Pipeline by Immune Pharmaceuticals Inc, H1 2017
  • Prostate Cancer - Pipeline by Immuneed AB, H1 2017
  • Prostate Cancer - Pipeline by Immunocore Ltd, H1 2017
  • Prostate Cancer - Pipeline by ImmunoFrontier Inc, H1 2017
  • Prostate Cancer - Pipeline by Immunomedics Inc, H1 2017
  • Prostate Cancer - Pipeline by Immupharma Plc, H1 2017
  • Prostate Cancer - Pipeline by IMPACT Therapeutics Inc, H1 2017
  • Prostate Cancer - Pipeline by Incanthera Ltd, H1 2017
  • Prostate Cancer - Pipeline by Inflection Biosciences Ltd, H1 2017
  • Prostate Cancer - Pipeline by InKemia IUCT Group SA, H1 2017
  • Prostate Cancer - Pipeline by Innate Immunotherapeutics Ltd, H1 2017
  • Prostate Cancer - Pipeline by Innovation Pharmaceuticals Inc, H1 2017
  • Prostate Cancer - Pipeline by Inovio Pharmaceuticals Inc, H1 2017
  • Prostate Cancer - Pipeline by Inspyr Therapeutics Inc, H1 2017
  • Prostate Cancer - Pipeline by Intech Biopharm Ltd, H1 2017
  • Prostate Cancer - Pipeline by Io Therapeutics Inc, H1 2017
  • Prostate Cancer - Pipeline by Ionis Pharmaceuticals Inc, H1 2017
  • Prostate Cancer - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2017
  • Prostate Cancer - Pipeline by Johnson & Johnson, H1 2017
  • Prostate Cancer - Pipeline by Jyant Technologies Inc, H1 2017
  • Prostate Cancer - Pipeline by KaloBios Pharmaceuticals Inc, H1 2017
  • Prostate Cancer - Pipeline by Karyopharm Therapeutics Inc, H1 2017
  • Prostate Cancer - Pipeline by Kite Pharma Inc, H1 2017
  • Prostate Cancer - Pipeline by Komipharm International Co Ltd, H1 2017
  • Prostate Cancer - Pipeline by Konruns Pharmaceutical Co Ltd, H1 2017
  • Prostate Cancer - Pipeline by Kura Oncology Inc, H1 2017
  • Prostate Cancer - Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2017
  • Prostate Cancer - Pipeline by LATITUDE Pharmaceuticals Inc, H1 2017
  • Prostate Cancer - Pipeline by Lidds AB, H1 2017
  • Prostate Cancer - Pipeline by Luye Pharma Group Ltd, H1 2017
  • Prostate Cancer - Pipeline by MacroGenics Inc, H1 2017
  • Prostate Cancer - Pipeline by Mallinckrodt Plc, H1 2017
  • Prostate Cancer - Pipeline by Mateon Therapeutics Inc, H1 2017
  • Prostate Cancer - Pipeline by MaxiVAX SA, H1 2017
  • Prostate Cancer - Pipeline by Meabco A/S, H1 2017
  • Prostate Cancer - Pipeline by Med Discovery SA, H1 2017
  • Prostate Cancer - Pipeline by MediaPharma Srl, H1 2017
  • Prostate Cancer - Pipeline by MediGene AG, H1 2017
  • Prostate Cancer - Pipeline by MedImmune LLC, H1 2017
  • Prostate Cancer - Pipeline by Mediolanum farmaceutici SpA, H1 2017
  • Prostate Cancer - Pipeline by MEI Pharma Inc, H1 2017
  • Prostate Cancer - Pipeline by Merck & Co Inc, H1 2017
  • Prostate Cancer - Pipeline by Merck KGaA, H1 2017
  • Prostate Cancer - Pipeline by Merrimack Pharmaceuticals Inc, H1 2017
  • Prostate Cancer - Pipeline by Microlin Bio Inc, H1 2017
  • Prostate Cancer - Pipeline by Millennium Pharmaceuticals Inc, H1 2017
  • Prostate Cancer - Pipeline by Minerva Biotechnologies Corp, H1 2017
  • Prostate Cancer - Pipeline by Mirati Therapeutics Inc, H1 2017
  • Prostate Cancer - Pipeline by Mithra Pharmaceuticals SA, H1 2017
  • Prostate Cancer - Pipeline by MolMed SpA, H1 2017
  • Prostate Cancer - Pipeline by Monopar Therapeutics LLC, H1 2017
  • Prostate Cancer - Pipeline by Morphotek Inc, H1 2017
  • Prostate Cancer - Pipeline by MTG Biotherapeutics Inc, H1 2017
  • Prostate Cancer - Pipeline by NewLink Genetics Corp, H1 2017
  • Prostate Cancer - Pipeline by NormOxys Inc, H1 2017
  • Prostate Cancer - Pipeline by Novartis AG, H1 2017
  • Prostate Cancer - Pipeline by Novogen Ltd, H1 2017
  • Prostate Cancer - Pipeline by Novus Therapeutics Inc, H1 2017
  • Prostate Cancer - Pipeline by Noxopharm Ltd, H1 2017
  • Prostate Cancer - Pipeline by Nymox Pharmaceutical Corp, H1 2017
  • Prostate Cancer - Pipeline by Oasmia Pharmaceutical AB, H1 2017
  • Prostate Cancer - Pipeline by Omeros Corp, H1 2017
  • Prostate Cancer - Pipeline by Omnitura Therapeutics Inc, H1 2017
  • Prostate Cancer - Pipeline by OncBioMune Pharmaceuticals Inc, H1 2017
  • Prostate Cancer - Pipeline by Oncodrone BV, H1 2017
  • Prostate Cancer - Pipeline by Oncogenex Pharmaceuticals Inc, H1 2017
  • Prostate Cancer - Pipeline by OncoMax, H1 2017
  • Prostate Cancer - Pipeline by OncoNOx ApS, H1 2017
  • Prostate Cancer - Pipeline by OncoTartis Inc, H1 2017
  • Prostate Cancer - Pipeline by OncoTherapy Science Inc, H1 2017
  • Prostate Cancer - Pipeline by Oncovir Inc, H1 2017
  • Prostate Cancer - Pipeline by Oncternal Therapeutics Inc, H1 2017
  • Prostate Cancer - Pipeline by Oneness Biotech Co Ltd, H1 2017
  • Prostate Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H1 2017
  • Prostate Cancer - Pipeline by ORCA Therapeutics BV, H1 2017
  • Prostate Cancer - Pipeline by Oribase Pharma, H1 2017
  • Prostate Cancer - Pipeline by Oric Pharmaceuticals Inc, H1 2017
  • Prostate Cancer - Pipeline by Orion Oyj, H1 2017
  • Prostate Cancer - Pipeline by Orphagen Pharmaceuticals Inc, H1 2017
  • Prostate Cancer - Pipeline by Oxford BioMedica Plc, H1 2017
  • Prostate Cancer - Pipeline by Panacea Pharmaceuticals Inc, H1 2017
  • Prostate Cancer - Pipeline by Patrys Ltd, H1 2017
  • Prostate Cancer - Pipeline by PDS Biotechnology Corp, H1 2017
  • Prostate Cancer - Pipeline by Peptron Inc, H1 2017
  • Prostate Cancer - Pipeline by PepVax Inc, H1 2017
  • Prostate Cancer - Pipeline by Pfizer Inc, H1 2017
  • Prostate Cancer - Pipeline by Pharmedartis GmbH, H1 2017
  • Prostate Cancer - Pipeline by Pharmicell Co Ltd, H1 2017
  • Prostate Cancer - Pipeline by Pharminox Ltd, H1 2017
  • Prostate Cancer - Pipeline by Philogen SpA, H1 2017
  • Prostate Cancer - Pipeline by Polaris Pharmaceuticals Inc, H1 2017
  • Prostate Cancer - Pipeline by Polyplus-Transfection SA, H1 2017
  • Prostate Cancer - Pipeline by Prima BioMed Ltd, H1 2017
  • Prostate Cancer - Pipeline by Progenics Pharmaceuticals Inc, H1 2017
  • Prostate Cancer - Pipeline by Provectus Biopharmaceuticals Inc, H1 2017
  • Prostate Cancer - Pipeline by Provenance Biopharmaceuticals Corp, H1 2017
  • Prostate Cancer - Pipeline by PSites Pharma GmbH, H1 2017
  • Prostate Cancer - Pipeline by Quintessence Biosciences Inc, H1 2017
  • Prostate Cancer - Pipeline by Radiomedix Inc, H1 2017
  • Prostate Cancer - Pipeline by RedHill Biopharma Ltd, H1 2017
  • Prostate Cancer - Pipeline by Regulaxis SAS, H1 2017
  • Prostate Cancer - Pipeline by RhoVac AB, H1 2017
  • Prostate Cancer - Pipeline by Rubicon Biotechnology Inc, H1 2017
  • Prostate Cancer - Pipeline by Sanofi, H1 2017
  • Prostate Cancer - Pipeline by Selexel Sarl, H1 2017
  • Prostate Cancer - Pipeline by Senhwa Biosciences Inc, H1 2017
  • Prostate Cancer - Pipeline by Serometrix LLC, H1 2017
  • Prostate Cancer - Pipeline by Shenogen Pharma Group Ltd, H1 2017
  • Prostate Cancer - Pipeline by Shire Plc, H1 2017
  • Prostate Cancer - Pipeline by Sierra Oncology Inc, H1 2017
  • Prostate Cancer - Pipeline by Sophiris Bio Inc, H1 2017
  • Prostate Cancer - Pipeline by Soricimed Biopharma Inc, H1 2017
  • Prostate Cancer - Pipeline by Sorrento Therapeutics Inc, H1 2017
  • Prostate Cancer - Pipeline by Sotio AS, H1 2017
  • Prostate Cancer - Pipeline by Steba Biotech SA, H1 2017
  • Prostate Cancer - Pipeline by Supratek Pharma Inc, H1 2017
  • Prostate Cancer - Pipeline by SynDevRx Inc, H1 2017
  • Prostate Cancer - Pipeline by SyntheX Inc, H1 2017
  • Prostate Cancer - Pipeline by TaiGen Biotechnology Co Ltd, H1 2017
  • Prostate Cancer - Pipeline by Taiho Pharmaceutical Co Ltd, H1 2017
  • Prostate Cancer - Pipeline by Taiwan Liposome Company Ltd, H1 2017
  • Prostate Cancer - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
  • Prostate Cancer - Pipeline by Takis Srl, H1 2017
  • Prostate Cancer - Pipeline by Targovax ASA, H1 2017
  • Prostate Cancer - Pipeline by Tarrex Biopharma Ltd, H1 2017
  • Prostate Cancer - Pipeline by Terpenoid Therapeutics Inc, H1 2017
  • Prostate Cancer - Pipeline by Tesaro Inc, H1 2017
  • Prostate Cancer - Pipeline by Teva Pharmaceutical Industries Ltd, H1 2017
  • Prostate Cancer - Pipeline by The Female Health Company, H1 2017
  • Prostate Cancer - Pipeline by Theravectys SA, H1 2017
  • Prostate Cancer - Pipeline by Threshold Pharmaceuticals Inc, H1 2017
  • Prostate Cancer - Pipeline by Tolero Pharmaceuticals Inc, H1 2017
  • Prostate Cancer - Pipeline by TRACON Pharmaceuticals Inc, H1 2017
  • Prostate Cancer - Pipeline by TREAT U SA, H1 2017
  • Prostate Cancer - Pipeline by Triphase Accelerator Corp, H1 2017
  • Prostate Cancer - Pipeline by TVAX Biomedical Inc, H1 2017
  • Prostate Cancer - Pipeline by Tyme Technologies Inc, H1 2017
  • Prostate Cancer - Pipeline by UbiVac LLC, H1 2017
  • Prostate Cancer - Pipeline by Ultimovacs AS, H1 2017
  • Prostate Cancer - Pipeline by Vaccibody AS, H1 2017
  • Prostate Cancer - Pipeline by ValiRx Plc, H1 2017
  • Prostate Cancer - Pipeline by Vasgen Ltd, H1 2017
  • Prostate Cancer - Pipeline by Vault Pharma Inc, H1 2017
  • Prostate Cancer - Pipeline by Vaxeal Holding SA, H1 2017
  • Prostate Cancer - Pipeline by Vaxon Biotech, H1 2017
  • Prostate Cancer - Pipeline by Vicore Pharma AB, H1 2017
  • Prostate Cancer - Pipeline by Vicus Therapeutics LLC, H1 2017
  • Prostate Cancer - Pipeline by Viralytics Ltd, H1 2017
  • Prostate Cancer - Pipeline by ViraTherapeutics GmbH, H1 2017
  • Prostate Cancer - Pipeline by VLP Therapeutics LLC, H1 2017
  • Prostate Cancer - Pipeline by Wilex AG, H1 2017
  • Prostate Cancer - Pipeline by WntResearch AB, H1 2017
  • Prostate Cancer - Pipeline by Xencor Inc, H1 2017
  • Prostate Cancer - Pipeline by Yungjin Pharm Co Ltd, H1 2017
  • Prostate Cancer - Pipeline by Zhejiang Hisun Pharmaceutical Co Ltd, H1 2017
  • Prostate Cancer - Dormant Projects, H1 2017
  • Prostate Cancer - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Prostate Cancer - Dormant Projects, H1 2017 (Contd..2), H1 2017
  • Prostate Cancer - Dormant Projects, H1 2017 (Contd..3), H1 2017
  • Prostate Cancer - Dormant Projects, H1 2017 (Contd..4), H1 2017
  • Prostate Cancer - Dormant Projects, H1 2017 (Contd..5), H1 2017
  • Prostate Cancer - Dormant Projects, H1 2017 (Contd..6), H1 2017
  • Prostate Cancer - Dormant Projects, H1 2017 (Contd..7), H1 2017
  • Prostate Cancer - Dormant Projects, H1 2017 (Contd..8), H1 2017
  • Prostate Cancer - Dormant Projects, H1 2017 (Contd..9), H1 2017
  • Prostate Cancer - Dormant Projects, H1 2017 (Contd..10), H1 2017
  • Prostate Cancer - Dormant Projects, H1 2017 (Contd..11), H1 2017
  • Prostate Cancer - Dormant Projects, H1 2017 (Contd..12), H1 2017
  • Prostate Cancer - Dormant Projects, H1 2017 (Contd..13), H1 2017
  • Prostate Cancer - Dormant Projects, H1 2017 (Contd..14), H1 2017
  • Prostate Cancer - Dormant Projects, H1 2017 (Contd..15), H1 2017
  • Prostate Cancer - Dormant Projects, H1 2017 (Contd..16), H1 2017
  • Prostate Cancer - Dormant Projects, H1 2017 (Contd..17), H1 2017
  • Prostate Cancer - Dormant Projects, H1 2017 (Contd..18), H1 2017
  • Prostate Cancer - Dormant Projects, H1 2017 (Contd..19), H1 2017
  • Prostate Cancer - Dormant Projects, H1 2017 (Contd..20), H1 2017
  • Prostate Cancer - Dormant Projects, H1 2017 (Contd..21), H1 2017
  • Prostate Cancer - Dormant Projects, H1 2017 (Contd..22), H1 2017
  • Prostate Cancer - Dormant Projects, H1 2017 (Contd..23), H1 2017
  • Prostate Cancer - Dormant Projects, H1 2017 (Contd..24), H1 2017
  • Prostate Cancer - Dormant Projects, H1 2017 (Contd..25), H1 2017
  • Prostate Cancer - Discontinued Products, H1 2017
  • Prostate Cancer - Discontinued Products, H1 2017 (Contd..1), H1 2017
  • Prostate Cancer - Discontinued Products, H1 2017 (Contd..2), H1 2017
  • Prostate Cancer - Discontinued Products, H1 2017 (Contd..3), H1 2017
  • Prostate Cancer - Discontinued Products, H1 2017 (Contd..4), H1 2017
  • Prostate Cancer - Discontinued Products, H1 2017 (Contd..5), H1 2017

List of Figures

  • Number of Products under Development for Prostate Cancer, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Top 10 Routes of Administration, H1 2017
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2017
  • Number of Products by Top 10 Molecule Types, H1 2017
  • Number of Products by Stage and Top 10 Molecule Types, H1 2017
Back to Top